Skin Cancer: Merkel Cell

    Actionable Target Abnormality Prevalence Clinical Experience with Targeted Agent
    PD-L1 Expression N/A Avelumab (PD-L1 inhibitor) (FDA approved):
    • Phase 2: RR 32% (CR 9%, PR 23%), responses ongoing in 23/28 pts at time of analysis (12)
    Pembrolizumab (PD-1 inhibitor):
    • Phase 2: RR 56% (CR 16%, PR 40%) (13)
    Other topics in Targets by Organ Site